April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Comparison of dual AAV vector approaches for large gene delivery to the retina
Author Affiliations & Notes
  • Livia S Carvalho
    Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA
  • Heikki T Turunen
    Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA
  • Maria Victoria Luna Velez
    Ophthalmology, University of Pennsylvania School of Medicine, F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Philadelphia, PA
  • Jean Bennett
    Ophthalmology, University of Pennsylvania School of Medicine, F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Philadelphia, PA
  • Luk H Vandenberghe
    Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA
  • Footnotes
    Commercial Relationships Livia Carvalho, None; Heikki Turunen, None; Maria Victoria Luna Velez, None; Jean Bennett, None; Luk Vandenberghe, GenSight Biologics (C), GenSight Biologics (I), GlaxoSmithKline Beecham (P), Novartis Pharmaceuticals (C), ReGenX Biosciences (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6002. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Livia S Carvalho, Heikki T Turunen, Maria Victoria Luna Velez, Jean Bennett, Luk H Vandenberghe; Comparison of dual AAV vector approaches for large gene delivery to the retina. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6002.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Retinal gene therapy has come a long way in the last ten years and the development and improvement of new gene delivery technologies has been exponential. The recent promising results from the first clinical trials for LCA have provided a major breakthrough in the field and have helped cement the use of recombinant adeno-associated viruses (AAV) as the major tool for retinal gene supplementation. One of the key problems of AAV however, is its limited capacity for packaging genomic information to a maximum of around 4.7kb. Previous studies have demonstrated that homologous recombination and/or ITR concatemerization of two overlapping AAV vectors can partially overcome the size limitation and help package larger constructs. Therefore the main aim of this study was to investigate and compare the use of different AAV dual-vector approaches to deliver large genes to the subretinal space.

Methods: We generated an oversized multicistronic AAV construct encoding four reporter genes in a single expression cassette separated by self-cleaving 2A peptides. This was then divided into two separate constructs: left and right, with one of the reporter genes split in half between the two. Three different approaches were tested to evaluate the reconstitution efficiency of the active transcript both in vitro and in vivo in the wild-type mouse retina. Correct reconstitution of the full transcript was assessed by β-galactosidase activity in vitro and by expression of fluorescence reporter genes in the retina.

Results: The three strategies investigated consisted of sequence overlap (OL), trans-splicing (TS) with splice donor and acceptor site and a hybrid (HB) of both. In vitro results showed that all three approaches showed reconstitution levels measured by β-galactosidase activity of 7.7%, 4.3% and 3.4% respectively for the HB, TS and OL strategies. However, analysis of murine retina injected subretinally with the different DUO strategies showed higher reconstitution from TS which was twice as efficient as HB and OL.

Conclusions: This study demonstrates that a dual AAV vector approach is capable of correct transgene reconstitution, although a TS strategy seems to be preferred in vivo compared to a HB approach in vitro. Low efficiency rates and in vivo and in vitro differences however indicate that further study is needed to better understand the reconstitution mechanisms behind a dual AAV strategy.

Keywords: 538 gene transfer/gene therapy • 411 adenovirus  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×